DOI: http://dx.doi.org/10.22516/25007440.236

Prevalencia de prescripción inapropiada de terapia supresora de ácido en adultos hospitalizados en un hospital general en Bogotá

Sebastian Posada Bustos, Nathalia de León Fernández, Rossmary González Morales, Jonathan Tihanyi Feldman, José Fernando Vera Chamorro

Resumen


Objetivo: Determinar la prevalencia de prescripción de terapia supresora de ácido (TSA) conformada por los inhibidores de la bomba de protones (IBP) y los antagonistas de los receptores H2 (AR-H2) en pacientes adultos hospitalizados en el Hospital Universitario Fundación Santa Fe de Bogotá (HU-FSFB) que no corresponda a las indicaciones de las guías de práctica clínica (GPC).

Métodos: Estudio observacional descriptivo de corte transversal que incluyó pacientes adultos hospitalizados en el HU-FSFB con prescripción de TSA de novo, determinando las indicaciones de TSA y comparándolas con las indicaciones validadas. Se excluyeron: pacientes con prescripción o consumo previo de TSA durante dos semanas, y pacientes internados en unidad de cuidados intensivos o con hospitalización menor a un día.

Resultados: Entre enero y julio de 2015, se incluyeron 306 pacientes con un promedio de edad de 56,6 ( años, con una prevalencia de prescripción de TSA sin indicación basada en la evidencia del 59,5%. Las indicaciones no basadas en la evidencia más comunes fueron: profilaxis sangrado por ulcera gastrointestinal en pacientes de bajo riesgo: 64,9% y causa no establecida en un 13,7%. Se encontró asociación estadísticamente significativa entre tiempo de hospitalización menor a siete días (OR: 2,39 IC 95% 1,4-3,9) y edad menor a 60 años (OR: 1,9 IC 95% 1,2-3,03) con prescripción inapropiada de TSA.

Conclusión: Existe una alta prevalencia (59,5%) de prescripción inapropiada de TSA en pacientes adultos hospitalizados con asociación positiva en menores de 60 años y corta hospitalización en el HU-FSFB.


Palabras clave


inhibidores de la bomba de protones; hospitalizados; guías de práctica clínica; antagonistas de los receptores H2

Texto completo:

PDF

Referencias


Madanick RD. Proton pump inhibitor side effects and drug interactions: much ado about nothing? Cleve Clin J Med 2011; 78:39-49

https://doi.org/10.3949/ccjm.77a.10087

Wallace JL, Sharkey KA. Chapter 45. Pharmacotherapy of Gastric Acidity, Peptic Ulcers, and Gastroesophageal Reflux Disease. En: Brunton LL, Chabner BA, Knollmann BC, editores. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12e. New York, NY: The McGraw-Hill Companies, 2011

Corleto VD, Festa S, Di Giulio E, Annibale B. Proton pump inhibitor therapy and potential long-term harm. Curr Opin Endocrinol Diabetes Obes 2014; 21:3-8

https://doi.org/10.1097/MED.0000000000000031

Hess MW, Hoenderop JG, Bindels RJ, Drenth JP. Systematic review: hypomagnesaemia induced by proton pump inhibition. Aliment Pharmacol Ther 2012; 36:405-413

https://doi.org/10.1111/j.1365-2036.2012.05201.x

Zipursky J, Macdonald E, Hollands S, Gomes T, Mamdani M, Paterson J et al. Proton Pump Inhibitors and Hospitalization with Hypomagnesemia: A Population-Based Case-Control Study. PLoS Medicine. 2014;11(9):e1001736.

https://doi.org/10.1371/journal.pmed.1001736

Yu EW, Bauer SR, Bain PA, Bauer DC. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med 2011; 124:519-526

https://doi.org/10.1016/j.amjmed.2011.01.007

Deshpande A, Pant C, Pasupuleti V, Rolston DD, Jain A, Deshpande N, Thota P, Sferra TJ, Hernandez AV. Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clin Gastroenterol Hepatol 2012; 10:225-233

https://doi.org/10.1016/j.cgh.2011.09.030

Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 2012; 107:1011-1019

https://doi.org/10.1038/ajg.2012.108

Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ 2011 22; 183:310-319.

https://doi.org/10.1503/cmaj.092129

Azab M, Doo L, Doo D, Elmofti Y, Ahmed M, Cadavona J et al. Comparison of the Hospital-Acquired Clostridium difficile Infection Risk of Using Proton Pump Inhibitors versus Histamine-2 Receptor Antagonists for Prophylaxis and Treatment of Stress Ulcers: A Systematic Review and Meta-Analysis. Gut and Liver. 2017;.

https://doi.org/10.5009/gnl16568

Nochaiwong S, Ruengorn C, Awiphan R, Koyratkoson K, Chaisai C, Noppakun K, et al. The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2017.

Wise J. Proton pump inhibitors are associated with risk of chronic kidney disease, study finds. BMJ. 2016;:i128.

https://doi.org/10.1136/bmj.i128

Barletta JF, Lat I, Micek S, Cohen H, Olsen K, Haas C. Off label use of gastrointestinal medications in the intensive care unit. J Intensive Care Med 2011; 26: 89-94

Barletta JF, Sclar DA. Use of proton pump inhibitors for the provision of stress ulcer prophylaxis: clinical and economic consequences. Pharmacoeconomics 2014; 32:5-13

https://doi.org/10.1007/s40273-013-0119-5

Farrell CP, Mercogliano G, Kuntz CL. Overuse of stress ulcer prophylaxis in the critical care setting and beyond. J Crit Care 2010; 25:214–220

https://doi.org/10.1016/j.jcrc.2009.05.014

Reid M, Keniston A, Heller JC, Miller M, Medvedev S, Albert RK. Inappropriate prescribing of proton pump inhibitors in hospitalized patients. J Hosp Med 2012; 7:421-425

https://doi.org/10.1002/jhm.1901

Savarino V, Dulbecco P, de Bortoli N, Ottonello A, Savarino E. The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal. European Journal of Internal Medicine. 2017;37:19-24.

https://doi.org/10.1016/j.ejim.2016.10.007

Thomas L, Culley EJ, Gladowski P, Goff V, Fong J, Marche SM. Longitudinal analysis of the costs associated with inpatient initiation and subsequent outpatient continuation of proton pump inhibitor therapy for stress ulcer prophylaxis in a large managed care organization. J Manag Care Spec Pharm 2010; 16:122-129

https://doi.org/10.18553/jmcp.2010.16.2.122

Gupta R, Garg P, Kottoor R, Munoz JC, Jamal MM, Lambiase LR, et al. Overuse of acid suppression therapy in hospitalized patients. SMJ 2010; 103:207-211.

https://doi.org/10.1097/SMJ.0b013e3181ce0e7a

Chia CT, Lim WP, Vu CK. Inappropriate use of proton pump inhibitors in a local setting. Singapore Med J 2014; 55:363-366

https://doi.org/10.11622/smedj.2014087

Bez C, Perrottet N, Zingg T, Leung Ki EL, Demartines N, Pannatier A. Stress ulcer prophylaxis in non-critically ill patients: a prospective evaluation of current practice in a general surgery department. J Eval Clin Pract 2013; 19:374-378

https://doi.org/10.1111/j.1365-2753.2012.01838.x

Bustamante Robles KY, Ticse Aguirre R, Cánepa Rondo IF, Costta Herrera CG, Vasquez Kunze S, Soto Arqui-igo L, Sosa Valle H. Frequency of proton pump inhibitor prescription based in clinical practice guidelines in hospitalized patients in two academic hospitals in Lima, Peru. Rev Gastroenterol Peru 2012; 32:44-49

Camacho R, Rodríguez A. Uso de los inhibidores de bomba de protones intravenosos en el Hospital Universitario de San Ignacio (HUSI). Universitas Médica. 2013;54(2):157-164

Machado-Alba J, et al. Prescribing patterns and economic costs of proton pump inhibitors in Colombia. Colombia Médica. 2013;44(1):13-18.

Scagliarini R, Magnani E, Praticò A, Bocchini R, Sambo P, Pazzi P. Inadequate Use of Acid-Suppressive Therapy in Hospitalized Patients and Its Implications for General Practice. Digestive Diseases and Sciences. 2005;50(12):2307-2311.

https://doi.org/10.1007/s10620-005-3052-4

Eid S, Boueiz A, Paranji S, Mativo C, BA R, Abougergi M. Patterns and Predictors of Proton Pump Inhibitor Overuse among Academic and Non-Academic Hospitalists. Internal Medicine. 2010;49(23):2561-2568.

https://doi.org/10.2169/internalmedicine.49.4064

Herzig SJ, Vaughn BP, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for nosocomial gastrointestinal tract bleeding. Arch Intern Med. 2011;171(11):991–7.

https://doi.org/10.1001/archinternmed.2011.14

Ahrens D, Behrens G, Himmel W, Kochen M, Chenot J. Appropriateness of proton pump inhibitor recommendations at hospital discharge and continuation in primary care. International Journal of Clinical Practice. 2012;66(8):767-773.

https://doi.org/10.1111/j.1742-1241.2012.02973.x


Métricas de artículo

Cargando métricas ...

Metrics powered by PLOS ALM

Enlaces refback

  • No hay ningún enlace refback.


Copyright (c) 2018 Revista Colombiana de Gastroenterología

Licencia de Creative Commons
Este obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.

ISSN versión impresa 0120-9957

ISSN versión en línea 2500-7440